menu
    • menu
    [{"orgOrder":0,"company":"Presage Biosciences","sponsor":"National Institutes of Health , National Cancer Institute , Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Presage Biosciences \/ National Institutes of Health , National Cancer Institute , Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Presage Biosciences \/ National Institutes of Health , National Cancer Institute , Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Fred Hutchinson Cancer Center , University of Washington , Northwell Health , Oregon Health and Science University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Presage Biosciences \/ Fred Hutchinson Cancer Center , University of Washington , Northwell Health , Oregon Health and Science University","highestDevelopmentStatusID":"6","companyTruncated":"Presage Biosciences \/ Fred Hutchinson Cancer Center , University of Washington , Northwell Health , Oregon Health and Science University"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MVC-101","moa":"EGFR","graph1":"Oncology","graph2":"Phase I","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Presage Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Presage Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Presage Biosciences \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Presage Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Rilvegostomig","moa":"PDCD1","graph1":"Oncology","graph2":"Phase I","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Presage Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Presage Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Rilvegostomig","moa":"PDCD1","graph1":"Oncology","graph2":"Phase I","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Presage Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Presage Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Subasumstat","moa":"SAE","graph1":"Oncology","graph2":"Phase I","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Presage Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Presage Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TAK-676","moa":"Stimulator of interferon genes protein (TMEM173)","graph1":"Oncology","graph2":"Phase I","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Presage Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Presage Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Bristol Myers Squibb , Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Motolimod","moa":"Toll-like receptor 8","graph1":"Oncology","graph2":"Phase I","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Presage Biosciences \/ Bristol Myers Squibb , Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Presage Biosciences \/ Bristol Myers Squibb , Bristol Myers Squibb"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Pure Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PBA-0405","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Presage Biosciences \/ Presage Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Presage Biosciences \/ Presage Biosciences"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Pure Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PBA-0405","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Presage Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Presage Biosciences \/ Pure Biologics","highestDevelopmentStatusID":"5","companyTruncated":"Presage Biosciences \/ Pure Biologics"},{"orgOrder":0,"company":"Presage Biosciences","sponsor":"Labcorp","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Presage Biosciences","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Presage Biosciences \/ Labcorp","highestDevelopmentStatusID":"5","companyTruncated":"Presage Biosciences \/ Labcorp"}]

    Find Clinical Drug Pipeline Developments & Deals by Presage Biosciences

    Menu

    Presage Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or ...

                            Details : Pembrolizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 14, 2024

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rilvegostomig

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, ...

                            Details : Rilvegostomig is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 16, 2024

                            Lead Product(s) : Rilvegostomig

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PBA-0405

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Pure Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

                            Details : PBA-0405 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 23, 2024

                            Lead Product(s) : PBA-0405

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Pure Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PBA-0405

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Pure Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Presage Announces FDA Study May Proceed to Evaluate Pre-GMP Candidate in Phase 0 Trial

                            Details : PBA-0405 is a novel ROR1 Inhibitor antibody with significantly improved therapeutic properties, which is currently being evaluated for the treatment of cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : PBA-0405

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Pure Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TAK-676

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

                            Details : TAK-676 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 02, 2023

                            Lead Product(s) : TAK-676

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MVC-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia

                            Details : MVC-101 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 18, 2021

                            Lead Product(s) : MVC-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Labcorp

                            Deal Size : $13.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Presage Sets the Stage for Commercial Expansion with Closing of $13M Financing and Collaborate with Merck and ...

                            Details : The proceeds from this financing will support expansion of Presage's existing network of clinical sites in the U.S. and Australia, as well as development of next-generation CIVO microdose injection devices designed to access a wider spectrum of cancers.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 02, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Labcorp

                            Deal Size : $13.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rilvegostomig

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

                            Details : Rilvegostomig is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 09, 2020

                            Lead Product(s) : Rilvegostomig

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Motolimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Bristol Myers Squibb , Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intratumoral Microdosing of Motolimod in HNSCC

                            Details : Motolimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 17, 2020

                            Lead Product(s) : Motolimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Bristol Myers Squibb , Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed

                            Presage Biosciences

                            U.S.A arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Subasumstat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

                            Details : TAK-981 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Head and Neck Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 22, 2019

                            Lead Product(s) : Subasumstat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth